Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

acapatamab

A half-life extended (HLE), bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA), fused to one that is directed against the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration acapatamab binds to both CD3 on cytotoxic T lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which results in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA, a tumor associated antigen, is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-PSMA/CD3 bispecific T-cell engager antibody AMG 160
anti-PSMA/CD3 BiTE antibody AMG 160
bispecific T-cell engager antibody AMG 160
BITE AMG 160
half-life extended bispecific T-cell engager antibody AMG 160
HLE-BiTE AMG 160
Code name:AMG 160
AMG-160
AMG160
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search